Premiere prophylaxis.

The phase 3 PREMER trial (n=118) demonstrates higher rates of delayed recall when receiving prophylactic cranial irradiation without versus with hippocampal avoidance at months 3 (22 → 5%) and 6 (33 → 7%). | De Dios, ASTRO 2019